- Citations, last 5 years
- 34
- Works, last 5 years
- 19
- h-index
- 21
- Scientists listed
- 3
- Grants since 2016
- 46
Grants received
2025–2026 · grant · Standard Grant
SBIR Phase I: A Novel Low Cost Intradermal Delivery Platform For Nucleic Acid Vaccines
Gaurav Byagathvalli · Io Therapeutics (United States) · funded by National Science Foundation
2025–2026 · grant · Standard Grant
SBIR Phase I: Image-Guided Controlled Release Platform for Intratumoral Immunoadjuvant Delivery
Stephen Linderman · Io Therapeutics (United States) · funded by National Science Foundation
2025–2028 · research · R44
Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis
Ricardo Valladares · Io Therapeutics (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Application of a novel dCasNano-based Epigenetic Editing to Treat Rett Syndrome
Yi-Ting Tsai · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R44
New approach for immune modulation against T1D
Weston Daniel · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease
John Paderi John Paderi John Paderi · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease
John Paderi John Paderi John Paderi · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
A Synergistic Multistrain Live Biotherapeutic Product for the Prevention and Treatment of Necrotizing Enterocolitis
Ricardo Valladares · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R41
SPNS2 inhibitors as renal fibrosis therapy
Webster L Santos · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2024 · grant · Standard Grant
STTR Phase I: Mechanically Controlled Drug Delivery Platform for Joint Environments
George Dodge · Io Therapeutics (United States) · funded by National Science Foundation
2023–2025 · cooperative agreement · UG3
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease
John Paderi John Paderi John Paderi · Io Therapeutics (United States) · funded by National Institutes of Health
2023 · research · R44
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease
John Paderi John Paderi John Paderi · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R44
New approach for immune modulation against T1D
Weston Daniel · Io Therapeutics (United States) · funded by National Institutes of Health
2023–2027 · cooperative agreement · UH3
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease
John Paderi · Io Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products
Ricardo Valladares · Io Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products
Ricardo Valladares · Io Therapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R41
Validating novel DNA repair deficient cancer therapy targets and small molecule compounds
Richard Lipkin · Io Therapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Novel immunotherapy against MOG antibody disease
Greg Barrett · Io Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · Cooperative Agreement
SBIR Phase II: A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines
Herbert Kavunja · Io Therapeutics (United States) · funded by National Science Foundation
2022–2025 · research · R44
Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products
Ricardo Valladares · Io Therapeutics (United States) · funded by National Institutes of Health
2022 · grant · Standard Grant
STTR Phase I: Protective T Cell Vaccine for SARS CoV-2 (COVID-19)
Lorraine Keller · Io Therapeutics (United States) · funded by National Science Foundation
2022–2025 · research · R41
Development of a Peptide Therapy for Corneal Wound Healing
Michael Flavin · Io Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Bone-targeted delivery of TGFβ inhibition for osteoarthritis
Xuchen Aimee Duan · Io Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine
Herbert Wanjala Kavunja · Io Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · research · R43
Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine
Herbert Wanjala Kavunja · Io Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Bone-targeted delivery of TGFβ inhibition for osteoarthritis
Xuchen Aimee Duan · Io Therapeutics (United States) · funded by National Institutes of Health
2021–2022 · research · R41
Transient Gene Therapy as Broad Spectrum Antiviral
Dusan Bogunovic · Io Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R41
DFMO Therapy for Polycystic Kidney Disease
Michael Peter Vitek · Io Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · research · R43
A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates
Herbert Wanjala Kavunja · Io Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R44
IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens
Clayton Duncan · Io Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R44
IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens
Clayton Duncan · Io Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R44
Advancing ARP-1536, an Anti-VE-PTP Antibody, as an Adjunctive Therapy for the Treatment of Sight-Threatening Retinopathies
Kevin G. Peters · Io Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · grant · Standard Grant
SBIR Phase I: Development of Bacteriophage Qbeta and Mutants as Carriers for Next Generation Vaccines
Herbert Kavunja · Io Therapeutics (United States) · funded by National Science Foundation
2019–2020 · research · R43
Pre-clinical development of synthetic transcription elongation factors for the treatment of Friedreich's ataxia
Aseem Z Ansari · Io Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · grant · Standard Grant
SBIR Phase I: Development of a genomic targeting drug delivery platform
Sean Jeffries · Io Therapeutics (United States) · funded by National Science Foundation
2018–2020 · research · R43
Novel Therapy for Huntington's Disease
Michael Peter Vitek · Io Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Cerberus therapy for metastatic disease
Erik Matthias Martinez Hackert · Io Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Polymeric nanoparticles for inductive browning of white adipose tissue
Meng Deng · Io Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Targeting TGF-beta growth factors to treat obesity
Erik Matthias Martinez Hackert · Io Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Developing a new therapeutic agent for Kabuki syndrome
Nicholas Katsanis · Io Therapeutics (United States) · funded by National Institutes of Health